Tecentriq Injection, Solution
Product Images NDC 50242-917

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tecentriq (NDC 50242-917). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tecentriq 01)

A Kaplan-Meier curve showing the probability of disease-free survival over time (months) comparing TECENTRIQ (atezolizumab) to Best Supportive Care. The graph plots survival probabilities on the vertical axis from 0.0 to 1.0 and time in months on the horizontal axis up to 54 months, with TECENTRIQ demonstrating higher survival probability across the timepoints.*

FDA Label Image

Figure 2 (Tecentriq 02)

A Kaplan-Meier survival curve comparing the probability of survival over time in months for TECENTRIQ (atezolizumab) versus chemotherapy. The graph shows higher survival probability for TECENTRIQ across approximately 37 months, with corresponding risk table values for both groups below the x-axis.*

FDA Label Image

Figure 3 (Tecentriq 03)

A Kaplan-Meier survival curve comparing the probability of survival over time in months between two treatment groups: TECENTRIQ plus bevacizumab, paclitaxel, and carboplatin versus bevacizumab, paclitaxel, and carboplatin alone. The graph shows survival probabilities on the y-axis and time in months on the x-axis, including the number of patients at risk over time for each group.*

FDA Label Image

Figure 4 (Tecentriq 04)

A Kaplan-Meier survival curve comparing probability of survival over time in months for two treatment groups: TECENTRIQ plus paclitaxel protein-bound and carboplatin, versus paclitaxel protein-bound and carboplatin alone. The graph includes a risk table showing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 5 (Tecentriq 05)

A Kaplan-Meier survival curve chart comparing the probability of survival over time (in months) between TECENTRIQ and Docetaxel. The chart shows survival probability on the vertical axis and time in months on the horizontal axis, with TECENTRIQ and Docetaxel curves and corresponding patient risk numbers displayed below.*

FDA Label Image

Figure 6 (Tecentriq 06)

A Kaplan-Meier overall survival curve compares TECENTRIQ with carboplatin and etoposide versus placebo with carboplatin and etoposide over 24 months. The survival percentages decrease over time for both groups, with patient risk numbers provided at various time points.*

FDA Label Image

Figure 7 (Tecentriq 07)

A Kaplan-Meier survival curve chart showing the probability of overall survival over time (months) for two groups: patients treated with TECENTRIQ plus bevacizumab, and those treated with sorafenib. The x-axis represents time in months, and the y-axis represents survival probability. The chart includes a table of the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 8 (Tecentriq 08)

A Kaplan-Meier survival curve comparing the probability of progression-free survival over 30 months between two treatment groups: TECENTRIQ plus cobimetinib and vemurafenib, and cobimetinib plus vemurafenib alone. The x-axis represents time in months, and the y-axis represents the probability of progression-free survival. Patient numbers at risk are shown below the x-axis for both groups at various time points.*

FDA Label Image

Principal Display Panel (20 mL Vial Carton)

Label for Tecentriq (atezolizumab) Injection, solution for intravenous infusion, 1200 mg/20 mL (60 mg/mL) strength. The product is a single-dose vial with no preservative, distributed by Genentech, Inc. The label includes directions for pharmacists to dispense the medication guide to patients.*

FDA Label Image

Principal Display Panel (14 mL Vial Carton)

Label for Tecentriq (atezolizumab) injection, solution for intravenous infusion. The vial strength indicated is 840 mg per 14 mL (60 mg/mL). This single-dose vial is manufactured by Genentech, Inc. Instructions note to discard unused portion and to dispense the accompanying medication guide to each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.